March 26, 2020

President Donald J. Trump
The White House
1600 Pennsylvania Avenue NW
Washington, DC 20500

Dear Mr. President:

As our nation battles the unprecedented challenge of the COVID-19 pandemic, your leadership in responding to the severity of the crisis is greatly appreciated. Stemming the spread of the coronavirus while providing critical support to the U.S. economy is the nation’s highest priority. We appreciate your Administration’s coordinated efforts, as well as the bipartisan leadership in Congress, to help ensure that our public health emergency and economic challenges are met. We, as patients, consumers, taxpayers, health care providers, payers, and members of the pharmaceutical and medical device pipeline, are ready to work with you and your Administration to ensure that America’s patients and our health care system receive the treatments they need throughout this public health crisis.

As you take action through Executive Order or in coordination with Congress, it is critical that those policies do not restrict access to — or destabilize the supply chain for — currently available pharmaceuticals or medical devices. At this time, while supply chains for a broad range of U.S. industries are stressed due to the global COVID-19 crisis and a number of factors related to the crisis have already raised concerns about shortages, it is important that we do not take any measures that could undermine the complex arrangements between firms that allow for efficient delivery of medicines to patients.

Today, patients in the United States and around the world depend on the use of global supply chains that facilitate ongoing access to needed medicines. These supply chains have been built over decades and include appropriate safeguards to ensure safety and efficacy of products. Keeping that supply chain strong is even more critical as we fight a global pandemic. That’s why the biopharmaceutical industry has been working together with the U.S. Food and Drug Administration to take significant steps to ensure continuity in our medicine supply. Proposals to drive all manufacturing to the United States not only overestimate the potential feasibility and underestimate the time and effort it would take to make such changes, but also misunderstand that a diverse pharmaceutical supply chain is precisely what enables the industry to respond quickly and make adjustments in its supply chain sourcing during natural emergencies and global public health crises.

We are committed to working with you to combat the COVID-19 crisis, ensure continued access to pharmaceuticals and devices for America’s patients and providers caring for them, and develop incentives that result in renewing the domestic manufacturing base for health care products in the United States. Thank you for considering our views and for your ongoing leadership during this unprecedented crisis.
Sincerely,

60 Plus Association
Academy of Managed Care Pharmacy
Advocacy & Awareness for Immune Disorders Association
The AIDS Institute
Allergy & Asthma Network
Alliance for Aging Research
American Autoimmune Related Diseases Association
American Behcet’s Disease Association
American Cancer Society Cancer Action Network
American Consumer Institute
American Diabetes Association
American Kidney Fund
Arthritis Foundation
ASPIRE: Alliance to Solve PANS & Immune-Related Encephalopathies
Association for Accessible Medicines
Asthma and Allergy Foundation of America
Autoimmune Encephalitis Alliance, Inc.
Beyond Celiac
Black Women’s Health Imperative
Center for Freedom and Prosperity
Conquer Myasthenia Gravis
Consumer Action
Consumer Healthcare Products Association
Council for Citizens Against Government Waste
Cutaneous Lymphoma Foundation
Dysautonomia International
Endocrine Society
FreedomWorks
Frontiers of Freedom
GO2 Foundation for Lung Cancer
Global Healthy Living Foundation
Healthcare Distribution Alliance
HealthHIV
HIV + Hepatitis Policy Institute
Immune Deficiency Foundation
Innovative Defense Foundation
International Foundation for Autoimmune & Autoinflammatory Arthritis
International Myeloma Foundation
International Pemphigus Pemphigoid Foundation
LUNGevity Foundation
Lupus and Allied Diseases Association, Inc.
Lupus Foundation of America
Marti Nelson Cancer Foundation
Mended Hearts & Mended Little Hearts
Mental Health America
Myasthenia Gravis Foundation of America
The Myositis Association
National Alliance on Mental Illness
National Alopecia Areata Foundation
National Consumers League
National Eczema Association
National Health Council
National Multiple Sclerosis Society
National Psoriasis Foundation
National Taxpayers Union
Osteogenesis Imperfecta Foundation
Partnership to Fight Chronic Disease
PhRMA
Prevent Cancer Foundation
R Street Institute
Sjögren’s Foundation
Spina Bifida Association
Susan G. Komen
Taxpayers Protection Alliance
USP
U.S. Pain Foundation
Us TOO International
Vitiligo Support International